Please login to the form below

Not currently logged in
Email:
Password:

Sarepta Therapeutics

This page shows the latest Sarepta Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK and pharma partner pilot data-sharing HTA approach

Duchenne UK and pharma partner pilot data-sharing HTA approach

Duchenne UK and pharma partner pilot data-sharing HTA approach. Pfizer, Roche and PTC Therapeutics are among those participating in Project Hercules. ... The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life

Latest news

  • Sarepta eyes FDA filing for DMD drug golodirsen after positive trial Sarepta eyes FDA filing for DMD drug golodirsen after positive trial

    The exon-skipping drug raised functional dystrophin levels. Sarepta is preparing to file a follow-up to its Duchenne muscular dystrophy (DMD) treatment Exondys 51 that seems to have greater efficacy. ... Sarepta says its goal is to be able to prove a

  • FDA approves first steroid for Duchenne muscular dystrophy FDA approves first steroid for Duchenne muscular dystrophy

    The agency granted orphan and priority review status for the drug, which is the second DMD treatment to be approved in the US after Sarepta Therapeutics' exon-skipping therapy Exondys 51

  • Sarepta soars as FDA clears its muscular dystrophy drug Sarepta soars as FDA clears its muscular dystrophy drug

    Sarepta soars as FDA clears its muscular dystrophy drug. Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns. ... Earlier this year, Sarepta Therapeutics told Muscular Dystrophy UK that they plan to apply to the EMA by the

  • FDA panel rejects BioMarin's muscular dystrophy drug FDA panel rejects BioMarin's muscular dystrophy drug

    A rival therapy from Sarepta Therapeutics called eteplirsen, which has a similar 'exon-skipping' mode of action to drisapersen, is due to come in front of the advisory committee in January, ... Sarepta is seeking approval of eteplirsen with a smaller

  • Sarepta seeks new CEO but says eteplirsen is on track Sarepta seeks new CEO but says eteplirsen is on track

    Sarepta Therapeutics' chief executive Chris Garabedian has stepped down just as its lead drug for Duchenne muscular dystrophy (DMD) is about to be submitted for approval in the US. ... PTC Therapeutics' Translarna (ataluren) - is already approved and

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics. ... Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in the competition to hustle ahead new DMD drugs to regulators. ... This month also saw CAR-T “ wunder-kid” Juno Therapeutics

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Minoryx Therapeutics adds to board of directors Minoryx Therapeutics adds to board of directors

    Dr Claude Nicaise has joined Barcelona, Spain-based Minoryx Therapeutics as an independent board member. ... He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics. ... Procter &Gamble. Reckitt Benckiser. Regeneron. Replicel. Roche. RPS. Sanofi. Santen. Sarepta Therapeutics.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Brandcast Health

Brandcast Health is a digital MedComms and patient-engagement agency who help our clients create and share engaging content. Our innovative...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics